McNeil recall complete
This article was originally published in The Tan Sheet
Executive Summary
A multiple-product recall initiated by McNeil Consumer & Specialty Pharmaceuticals was actually completed in October and is no longer "ongoing," as stated in FDA's Jan. 11 Enforcement Report (See Recalls & Court actions p. 14). The recall affected various lots of Tylenol and Motrin products rejected in the normal course of manufacturing process controls and intended for destruction under usual protocols. The listed products were stolen and "possibly diverted to retail stores" through "secondary markets" according to a McNeil spokesperson...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab With 15 New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.